Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Seyed Mohammad Hashemi Professor of Cardiology CHRONIC STABLE ANGINA Non Pharmachologic Therapy ANGINA A careful history and physical examination is critical to accurately establish the diagnosis of angina pectoris and to exclude other causes of chest pain. PATHOPHYSIOLOGY OF ISCHEMIC CHEST PAIN Angina is caused by myocardial ischemia which occurs whenever myocardial oxygen demand exceeds oxygen supply Provoking Factors Of The Chest Pain Angina is often elicited by activities and situations which increase myocardial oxygen demand, including physical activity, cold, emotional stress, sexual intercourse, meals, or lying down . It has been strongly recommended that patients also be questioned about cocaine use . QUALITY OF THE CHEST PAIN Angina is often characterized more as a discomfort than pain, and may be difficult to describe squeezing, tightness, pressure, constriction, strangling, burning, heart burn, fullness in the chest,, lump in throat, ache, heavy weight on chest (elephant sitting on chest) Levine sign Radiation Of The Chest Pain Angina often radiates to other parts of the body including the upper abdomen (epigastric), shoulders, arms (upper and forearm), wrist, fingers, neck and throat, lower jaw and teeth (but not upper jaw), and rarely to the back (specifically the interscapular region). Site Of The Chest Pain Visceral Pain Visceral fibers enter the spinal cord at several levels leading to poorly localized, poorly characterized pain. (discomfort, heaviness, dull, aching) Heart, blood vessels, esophagus and visceral pleura are innervated by visceral fibers Because of dorsal fibers can overlap three levels above or below, disease of thoracic origin can produce pain anywhere from the jaw to the epigastrum Site Of The Chest Pain Parietal Pain Parietal pain, in contrast to visceral pain, is described as sharp and can be localized to the dermatome superficial to the site of the painful stimulus. The dermis and parietal pleura are innervated by parietal fibers. Timing Of The Chest Pain Angina occurs more commonly in the morning due to a morning diurnal increase in sympathetic tone. Enhanced sympathetic activity raises heart rate, blood pressure, vessel tone and resistance (resulting in a reduced vessel diameter which causes any fixed lesion to be more occlusive), and platelet aggregability. Time Of The Chest Pain More than 5 min and less than 20 min. ASSOCIATED SYMPTOMS OF THE CHEST PAIN most common : shortness of breath, may reflect mild pulmonary congestion resulting from ischemiamediated diastolic dysfunction. Other symptoms may include belching, nausea, indigestion, diaphoresis, dizziness, lightheadedness, clamminess, and fatigue. The 5/24/2017 THE GOALS OF THE THERAPY OF STABLE ANGINA INCLUDE: Relief of symptoms (To improve quality of life) Prevention or slowing of disease progression Prevention of future cardiac events, such as MI, unstable angina, or the need for revascularization Improvement in survival 16 THESE GOALS CAN BE ACHIEVED WITH A VARIETY OF MODALITIES INCLUDING; Nonpharmacologic and lifestyle measures Medical therapy, Percutaneous coronary intervention (PCI), surgical revascularization (CABG). ACC/AHA GUIDELINES FOR TREATMENT OF RISK FACTORS (CLASS I) AND SPECIFIC GOALS 1. Treatment of hypertension according to Joint National Conference VI guidelines Blood pressure <140/90 or 130/85 mm Hg if heart failure or renal insufficiency; <130/85 mm Hg if diabetes 2. Smoking cessation therapy Smoking Complete cessation ACC/AHA GUIDELINES FOR TREATMENT OF RISK FACTORS (CLASS I) AND SPECIFIC GOALS 3. Management of diabetes Diabetes management HbA1c <7% 4. Comprehensive cardiac rehabilitation program (including exercise) Physical activity Minimum goal: 30 min 3 or 4 d/w Optimal goal: daily ACC/AHA GUIDELINES FOR TREATMENT OF RISK FACTORS (CLASS I) AND SPECIFIC GOALS 5. LDL-lowering therapy in patients with documented or suspected CAD and LDL cholesterol ≥130 mg/dl, with a target LDL of <100 mg/dl Lipid management Primary goal: LDL <100 mg/dl Secondary goal: If triglycerides ≥200 mg/dl, then non-HDL should be <130 mg/dl Therapy to lower non-HDL cholesterol in patients with documented or suspected CAD and triglycerides >200 mg/dl, with a target non-HDL cholesterol <130 mg/dl ACC/AHA GUIDELINES FOR TREATMENT OF RISK FACTORS (CLASS I) AND SPECIFIC GOALS 6. Weight reduction in obese patients in the presence of hypertension, hyperlipidemia, or diabetes mellitus Weight management BMI 18.5–24.9 kg/m2 ACC/AHA GUIDELINES FOR TREATMENT OF RISK FACTORS (CLASS IIB) 1. Folate therapy in patients with elevated homocysteine levels 2. Identification and appropriate treatment of clinical depression to improve CAD outcomes 3. Intervention directed at psychosocial stress reduction ACC/AHA GUIDELINES FOR TREATMENT OF RISK FACTORS (CLASS III) 1. Initiation of hormone replacement therapy in postmenopausal women for the purpose of reducing cardiovascular risk A 2. Vitamins C and E supplementation A 3. Chelation therapy C 4. Garlic C 5. Acupuncture C 6. Coenzyme Q C WALK-THROUGH ANGINA PHENOMENON DURING EXERCISE occurrence of mild angina during the first stages of exercise with disappearance of chest pain at higher workloads despite a greater exercise. CURRENT NONPHARMACOLOGIC ANTIANGINAL STRATEGIES Exercise Training Enhanced external counterpulsation (EECP) Endothelial function Promotes coronary collateral formation Peripheral vascular resistance Ventricular function Placebo effect CURRENT NONPHARMACOLOGIC ANTIANGINAL STRATEGIES Transmyocardial revascularization (TMR) Sympathetic denervation Angiogenesis Spinal cord stimulation (SCS) Neurotransmission of painful stimuli Release of endogenous opiates Redistributes myocardial blood flow to ischemic areas TMR Surgical surgeons use the laser to make between 20 and 40 tiny (one-millimeter-wide) RATIONALE improved perfusion by stimulation of angiogenesis potential placebo effect anesthetic effect mediated by the destruction of sympathetic nerves carrying pain-sensitive afferent fibers Peri-procedural infarction. PERCUTANEOUS TMR Percutaneous EECP EECP Increases arterial blood pressure and retrograde aortic blood flow during diastole (diastolic augmentation). Cuffs are wrapped around the patients legs and sequential pressure (300mmHg) is applied in early diastole. PATIENT SELECTION Angina class III/IV Refractory to medical therapy Reversible ischemia of the free wall not amenable for revascularization Excluded if LVEF<20% or had current major illness